Literature DB >> 6803878

Cyclophosphamide treatment of systemic lupus erythematosus: risk of bladder cancer exceeds benefit.

R W Elliott, D M Essenhigh, A R Morley.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6803878      PMCID: PMC1496855          DOI: 10.1136/bmj.284.6323.1160

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


× No keyword cloud information.
  2 in total

1.  Carcinoma of the urinary bladder in patients receiving cyclophosphamide.

Authors:  R L Wall; K P Clausen
Journal:  N Engl J Med       Date:  1975-08-07       Impact factor: 91.245

2.  Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs.

Authors:  L J Kinlen; A G Sheil; J Peto; R Doll
Journal:  Br Med J       Date:  1979-12-08
  2 in total
  8 in total

1.  Apheresis therapy: spin-drying the blood.

Authors:  T J Hamblin
Journal:  Br Med J (Clin Res Ed)       Date:  1982-10-23

Review 2.  The treatment of lupus nephritis.

Authors:  J S Cameron
Journal:  Pediatr Nephrol       Date:  1989-07       Impact factor: 3.714

Review 3.  Malignancy and systemic lupus erythematosus.

Authors:  Sasha Bernatsky; Ann Clarke; Rosalind Ramsey-Goldman
Journal:  Curr Rheumatol Rep       Date:  2002-08       Impact factor: 4.592

4.  Cancer risk in a cohort of patients with systemic lupus erythematosus (SLE) in California.

Authors:  Arti Parikh-Patel; Richard H White; Mark Allen; Rosemary Cress
Journal:  Cancer Causes Control       Date:  2008-04-02       Impact factor: 2.506

5.  Bladder carcinoma following cyclophosphamide therapy. A case report.

Authors:  H Kiesswetter; N Baloch; J Flamm
Journal:  Int Urol Nephrol       Date:  1985       Impact factor: 2.370

Review 6.  Comparative activity of ifosfamide and cyclophosphamide.

Authors:  W Brade; S Seeber; K Herdrich
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

Review 7.  Drug-induced bladder and urinary disorders. Incidence, prevention and management.

Authors:  M J Drake; P M Nixon; J P Crew
Journal:  Drug Saf       Date:  1998-07       Impact factor: 5.606

8.  Risk of leukaemia in ovarian tumour and breast cancer patients following treatment by cyclophosphamide.

Authors:  J F Haas; B Kittelmann; W H Mehnert; W Staneczek; M Möhner; J M Kaldor; N E Day
Journal:  Br J Cancer       Date:  1987-02       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.